Zydus Lifesciences Limited — Updates, 14-02-2025: Press Release

Zydus Lifesciences Ltd. has entered into an exclusive licensing, supply, and commercialization agreement with Zhuhai Beihai Biotech Co., Ltd. for BEIZRAY, an Albumin Solubilized Docetaxel Injection, a 505(B)(2) product targeting the US market. Beihai Biotech will handle manufacturing and supply, while Zydus takes charge of commercialization. The agreement includes upfront payments, milestone payments based on sales targets, and a share of net profits from BEIZRAY.

BEIZRAY represents a significant advance as it is the first clinically validated formulation of Docetaxel devoid of harmful synthetic excipients, thus reducing adverse events. Approved for treating various cancers, BEIZRAY enters a market with an annual volume uptake of approximately 531,000 units in the US. This strategic alliance positions Zydus to address unmet medical needs in oncology, enhancing its market presence and delivering vital therapies to a broader patient base. Investors should observe this development closely, as it could lead to potential growth and strengthened positioning in the oncology sector.